Higher lung deposition with Respimat® Soft Mist™ Inhaler than HFA-MDI in COPD patients with poor technique
Authors:
- 1 December 2008
- journal article
- research article
- Vol. 3 (4) , 763-770
Abstract
Aerosols delivered by Respimat® Soft Mist™ Inhaler (SMI) are slower-moving and longer-lasting than those from pressurized metered-dose inhalers (pMDIs), improving the efficiency of pulmonary drug delivery to patients. In this four-way cross-over study, adults with chronic obstructive pulmonary disease (COPD) and with poor pMDI technique received radiolabelled Berodual® (fenoterol hydrobromide 50 μg/ipratropium bromide 20 μg) via Respimat® SMI or hydrofluoroalkane (HFA)-MDI (randomized order) on test days 1 and 2, with no inhaler technique training. The procedure was repeated on test days 3 and 4 after training. Deposition was measured by gamma scintigraphy. All 13 patients entered (9 males, mean age 62 years; FEV1 46% of predicted) inhaled too fast at screening (peak inspiratory flow rate [IF]: 69–161 L/min). Whole lung deposition was higher with Respimat® SMI than with pMDI for untrained (37% of delivered dose vs 21% of metered dose) and trained patients (53% of delivered vs 21% of metered dose) (pSign-Test].15; pANOVA < = 0.05). Training also improved inhalation profiles (slower average and peak IF as well as longer breath-hold time). Drug delivery to the lungs with Respimat® SMI is more efficient than with pMDI, even with poor inhaler technique. Teaching patients to hold their breath as well as to inhale slowly and deeply increased further lung deposition using Respimat® SMI.Keywords
This publication has 23 references indexed in Scilit:
- Clinical efficacy and safety of the combination of ipratropium bromide and fenoterol inhaled via the Respimat© Soft Mist ™ inhaler for relief of airflow obstructionExpert Review of Respiratory Medicine, 2008
- Comparison of the Aerosol Velocity and Spray Duration of Respimat® Soft Mist™ Inhaler and Pressurized Metered Dose InhalersJournal of Aerosol Medicine, 2005
- Assessing lung deposition of inhaled medicationsRespiratory Medicine, 1999
- Lung Deposition of Fenoterol and Flunisolide Delivered Using a Novel Device for Inhaled MedicinesChest, 1998
- Efficient Delivery to the Lungs of Flunisolide Aerosol From a New Portable Hand-Held Multidose NebulizerJournal of Pharmaceutical Sciences, 1996
- Beta2Adrenergic Agonists–Oral or Aerosol for the Treatment of Asthma?Journal of Asthma, 1990
- Comparisons of Planar and Tomographic Gamma Scintigraphy to Measure the Penetration Index of Inhaled AerosolsAmerican Review of Respiratory Disease, 1989
- CLINICAL CONSEQUENCES OF INADEQUATE INHALATION TECHNIQUE IN ASTHMA THERAPY1987
- Problems patients have using pressurized aerosol inhalers.1982
- How should a pressurized beta-adrenergic bronchodilator be inhaled?1981